Option chain shows key data for Tibet Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tibet Pharmaceuticals.

Tibet Pharmaceuticals (OTC:TBET) Stock, Option Chain

Tibet Pharmaceuticals Inc is a specialty pharmaceutical company focusing on the research, development, manufacturing and marketing of modernized traditional Tibetan medicines.

Long Ideas

News

Short Ideas

Small Cap

Global

Trading Ideas

ACRX

SPEX

TBET

Benzinga&#39;s Microcap Movers for Wednesday March 7, 2012

Tibet Pharmaceuticals, Inc. Announces Receipt of Non-Binding &#34;Going Private&#34; Proposal at $3.00 Per Share 

Rumors

After-Hours Center

Movers

CMLP

VRTX

Benzinga&#39;s M&amp;A Chatter for Monday February 27, 2012

TIBET PHARMACEUTICALS INC by Tibet Pharmaceuticals, Inc.

Tibet Pharmaceuticals Inc

Below are highlights from Benzinga's daily coverage of microcap securities making big moves:

Spherix Incorporated

Shares of Spherix Incorporated (NASDAQ: <a class="ticker" href="/stock/spex#NASDAQ">SPEX</a>), the Bethesda, MD developer of pharmaceutical products, rose 21% Wednesday on 24 times the average volume.

Spherix Incorporated (NASDAQ: <a class="ticker" href="/stock/spex#NASDAQ">SPEX</a>) announced Thursday that one of its drug candidates, SPX-106T, arrested development and reduced atherosclerotic plaque area in the aortic arch, thoracic aorta and sinus of Valsalva in mice genetically predisposed to cardiovascular disease. Atherosclerosis can lead to myocardial infarction and stroke. Each year, about 770,000 people in the United States experience their first MI, and about one-third of these events are fatal.

Spherix Incorporated closed at $1.01 on Wednesday.

AcelRx Pharmaceuticals

Shares of AcelRx Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/acrx#NASDAQ">ACRX</a>), the Redwood, CA developer of specialty pharmaceutical, rose 24% Wednesday on 92 times the average daily volume.

AcelRx Pharmaceuticals reported dosing of the first patient in a Phase 3 study for ARX-01 Tuesday, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia system. This first ARX-01 Phase 3 study is a randomized, double-blind, placebo-controlled efficacy and safety trial in adults following open abdominal surgery. Approximately 150 adults, randomized 2:1 to active or placebo groups, will be treated for post-operative pain for a minimum of 48 hours and, as needed, up to 72 hours after randomization. The study will be conducted at 12 academic and 
community hospitals in the United States.

AcelRx closed at $3.50 on Wednesday.

Tibet Pharmaceuticals

Shares of Tibet Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>), the Hong Kong specialty pharmaceutical company, rose 12.5% Wednesday on 7 times the average daily volume.

A <a href="http://seekingalpha.com/article/416181-tibet-pharmaceuticals-the-next-china-stock-that-is-going-private">Seeking Alpha</a> article suggested Tibet would be the next Chinese company to be taken private. 

Tibet pharmaceuticals closed at $1.44 on Wednesday.

Benzinga's Microcap Movers for Wednesday March 7, 2012

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) today announced that its Board of Directors has received a non-binding proposal letter from its Chairman and Chief Executive Officer, Mr. Hong Yu, for Mr. Yu to acquire all of the outstanding shares of the Company's common stock not currently owned by Mr. Yu, in a going private transaction for $3.00 per share in cash subject to certain conditions. According to the proposal letter, the acquisition is intended to be financed with a combination of debt and equity capital to be secured by Mr. Yu. Mr. Yu currently beneficially owns approximately 22.1% of TBET's common stock. A copy of the text of Mr. Yu's proposal letter is set forth at the end of this press release.

TBET's Board of Directors has formed a special committee consisting solely of independent directors (the "Special Committee") to consider, among other things, any proposal made by Mr. Yu, and the Special Committee will retain an independent counsel as its legal advisor to assist the Special Committee in its work. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that a transaction with Mr. Yu or any other transaction will be approved or consummated. The Company does not intend to disclose developments regarding these matters unless and until its Board of Directors determines there is a need to update the market.

Tibet Pharmaceuticals, Inc. Announces Receipt of Non-Binding "Going Private" Proposal at $3.00 Per Share 

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Monday February 27, 2012:

Tibet Pharmaceuticals Announces Intent to Go Private

The Offer: Tibet Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>), announced Monday that:
 "In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation. 

We're conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result," said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "The Company will take all necessary legal measures to defend itself against any untrue reports and to protect the interests of shareholders."

The Company also announced its intent to accept a "going private" proposal by Mr. Hong Yu, and cease its public company status. "In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,"said Mr. Hong Yu, "delisting details will be announced shortly".

Tibet Pharmaceuticals closed at $1.50 Monday, a gain of 108% on 190 times the average daily volume.

Crestwood Midstream Partners and Crestwood Holdings to Acquire Antero Resources' Marcellus Shale Gathering Assets for $375M

The Deal: Crestwood Midstream Partners (NYSE: <a class="ticker" href="/stock/cmlp#NYSE">CMLP</a>) and Antero Resources Appalachian Corporation announced Monday the execution of definitive agreements whereby CMLP and Crestwood Holdings, through a newly formed joint venture, have agreed to acquire certain of Antero's Marcellus Shale gathering system assets located in Harrison and Doddridge Counties, West Virginia for $375 million in cash plus an earn-out which would allow Antero to earn additional purchase price payments of up to $40 million based upon average annual production levels achieved during 2012 and 2013. 

Additionally, at closing, the parties have agreed to enter into a 20-year gas gathering and compression agreement, which will provide for an Area of Dedication of approximately 127,000 gross acres, or 104,000 net acres, largely located in the rich gas window of the southwestern core of the Marcellus Shale play. 

The transaction will have a January 1, 2012 effective date and is expected to close in March 2012, subject to regulatory approvals and customary closing conditions.

Crestwood Midstream Partners closed at $29.21 Monday, a gain of 0.97% for the day on 70% of the average daily volume.

Pfizer Acquires Alacer Corp

The Deal: Pfizer (NYSE: <a class="ticker" href="/stock/pfe#NYSE">PFE</a>) announced Monday the acquisition of privately-held Alacer Corp.

Based in Foothill Ranch, California, Alacer is well-known among health-conscious consumers as a provider of Vitamin C supplement products. It produces almost 500 million packets of Emergen-C annually, and its products are sold in health food stores, supermarkets, drug stores, mass merchandisers and club stores nationwide.

Financial terms of the transaction were not disclosed. Lazard acted as financial advisor to Pfizer, and DLA Piper acted as legal advisor to Pfizer, in connection with the acquisition. 

Pfizer closed at $21.26 Monday, a gain of 0.38% for the day on 85% of average volume.

Hearing Bristol-Myers Squibb Raises Offer for Vertex Pharmaceuticals

The Rumor: Hearing chatter that Bristol-Myers Squibb (NYSE: <a class="ticker" href="/stock/bmy#NYSE">BMY</a>) is raising its offer to acquire Vertex Pharmaceuticals (NASDAQ: <a class="ticker" href="/stock/vrtx#NASDAQ">VRTX</a>) to $57 per share, according to sources. The previous offer was rumored to be $50.

Spokespersons for Bristol-Meyers and Vertex could not be reached for comment, though both had previously declined comment.

Vertex Pharmaceuticals closed at $38.69 Monday, a gain of 0.78% for the day on 69% of the average daily volume.

Benzinga's M&A Chatter for Monday February 27, 2012

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) today announced that, 

 "In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation. We're conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result," said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "The Company will take all necessary legal measures to defend itself against any untrue reports and to protect the interests of shareholders."

The Company also announced its intent to accept a "going private" proposal by Mr. Hong Yu, and cease its public company status. "In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,"said Mr. Hong Yu, "delisting details will be announced shortly".

Tibet Pharmaceuticals Announces Intent to Go Private 

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) today announced that it has signed a Letter of Intent ("LOI") to cooperate with Anhui Taihe Pharmaceutical Group Co., Ltd., a wholesale pharmaceutical distribution company based in Anhui province with a network across 16 provinces and municipalities in China.

Contracts

Tibet Pharmaceuticals Signs Letter of Intent to Cooperate With Anhui Taihe Pharmaceutical Group  

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) announced today that it has engaged Sherb &amp; Co., LLP as its new independent auditor. Sherb &amp; Co. will commence its work immediately with the review of the Company's third quarter financial statements, which are to be included in the Company's upcoming form 10-Q.

Tibet Pharmaceuticals Announces Appointment of Sherb & Co., LLP as New Independent Auditor  

Atrinsic Inc (NASDAQ: <a class="ticker" href="/stock/atrn#NASDAQ">ATRN</a>) shares surged 52.44% to $3.43 at 9:45 am. Atrinsic reported that its streaming music application is now available for download through Apple's App Store.

Kona Grill Inc (NASDAQ: <a class="ticker" href="/stock/kona#NASDAQ">KONA</a>) climbed 34.03% to $7.05. KONA raised its third-quarter financial forecast.

Tibet Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) surged 22.46% to $1.69. TBET had $29.52 million in total cash and no debt for the recent quarter.

Cumulus Media Inc (NASDAQ: <a class="ticker" href="/stock/cmls#NASDAQ">CMLS</a>) shares advanced 11.60% to $2.79. CMLS' trailing-twelve-month operating margin is 28.97%.

Intraday Update

Markets

ATRN

CMLS

KONA

Morning Market Movers

The NASDAQ Stock Market (Nasdaq: <a class="ticker" href="/stock/ndaq#Nasdaq">NDAQ</a>) announced today that trading in Tibet Pharmaceuticals, Inc. (Nasdaq: <a class="ticker" href="/stock/tbet#Nasdaq">TBET</a>) is scheduled to resume on Tuesday, September 13, 2011 at 1:30 p.m., Eastern Time. Trading in the company's stock was previously halted on September 12, 2011.

NDAQ

NASDAQ Scheduled Resumption in Tibet Pharmaceuticals for 1:30 PM

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) today announced the search for a new auditor as it learned that its independent certifying accountant, Acquavella, Chiarelli, Shuster, Berkower &amp; Co., LLP, resigned as Tibet Pharmaceuticals' independent registered public accounting firm.

The resignation was not due to any disagreement with the company or any concerns about the company's financials, instead, it was in relation to ACSB pulling out of China. Because ACSB resigned, neither Tibet Pharmaceuticals' audit committee nor the board of directors recommended or approved the action. Instead, they learned of ACSB's resignation through a letter dated September 6, 2011. 

The principal accountant's reports of ACSB on Tibet's financial statements for the years ended December 31, 2009 and 2010 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

Tibet Pharmaceuticals Announces Search for New Auditor Upon Resignation of ACSB 

Tibet Pharma Halted

Pro-Dex Inc (NASDAQ: <a class="ticker" href="/stock/pdex#NASDAQ">PDEX</a>) dipped 25.45% to $2.05 at 9:55 am. PDEX's trailing-twelve-month ROE is -22.05%. 

Tibet Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) shares dropped 24.00% to $1.52. TBET's trailing-twelve-month revenue is $33.58 million.

Rubicon Minerals Corporation (AMEX: <a class="ticker" href="/stock/rby#AMEX">RBY</a>) shares moved down 15.55% to $4.02. RBY reported positive Preliminary Economic Assessment for its 100% owned F2 Gold System, part of its Phoenix Gold Project.

EXFO Inc (NASDAQ: <a class="ticker" href="/stock/exfo#NASDAQ">EXFO</a>) fell 15.42% to $7.57. EXFO reported downbeat Q3 results.

Movers & Shakers

EXFO

PDEX

Morning Market Losers 

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>) today announced that effective as of June 6, 2011 its Chairman, Mr. Hong Yu, replaces Mr. Taylor Guo as CEO of Tibet Pharmaceuticals.

Taylor Guo leaves Tibet Pharmaceuticals to pursue other interests while Hong Yu, the Chairman of Tibet Pharmaceuticals and founder of its operating entity in China, takes a more active role in the Company's development initiatives and investor outreach. Taylor Guo will remain a director of the Company for the foreseeable future.

Management

Tibet Pharmaceuticals Announces New CEO

Tibet Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/tbet#NASDAQ">TBET</a>), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the release of an in-depth nitiation report by Patrick Murphy, CFA, principal of fee-based, third-party research firm Murphy Analytics.

In his report, Mr. Murphy discusses Tibet Pharmaceuticals, its current portfolio of five traditional Tibetan medicine products, and initiates coverage with a 12-month price target of $11.00 per share.

Analyst Ratings

Tech

Murphy Analytics Initiates Research Coverage on Tibet Pharmaceuticals (TBET)

Tibet Pharmaceuticals, Inc. (Nasdaq: TBET) today announced that it has closed its initial public offering of 3,000,000 shares of common stock at a public offering price of $5.50 per share.
The size of the offering closed at the maximum end of the 2,500,000 to 3,000,000 share range as previously disclosed in Tibet's registration statement filed with the U.S. Securities and Exchange Commission. There were over 1,000 investors that purchased shares in the offering. 
The common shares are expected to begin trading mid-morning tomorrow, January 25, 2011, under the ticker symbol "TBET" on the Nasdaq Global Market.

Comments

Tibet Pharmaceuticals

Tibet Pharmaceuticals (TBET) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga